3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Sarcoma
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Endocrine
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
20
Triple Negative Breast Neoplasms
14
Ovarian Neoplasms
7
Melanoma
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Endometrial Neoplasms
3
Carcinoma, Hepatocellular
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
pembrolizumab
3
toripalimab
1
spartalizumab
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Ipilimumab
1
Interleukin-2
1
Immunotherapy
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nasopharyngeal Carcinoma
×
Ipilimumab
×
Breast
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled